In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1

Journal of Virology

Volumn 80, Issue 9, 2006, Pages 4440-4446

  Hossain, Mohammad M ^a   Parniak, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE VIRUS; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MICROBICIDAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANILIDES; CELL LINE; CELL-FREE SYSTEM; COCULTURE TECHNIQUES; DRUG RESISTANCE, VIRAL; FURANS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646173910     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.9.4440-4446.2006     Document Type: Article

References (58)

1. Abner, S. R., P. C. Guenthner, J. Guarner, K. A. Hancock, J. E. Cummins, A. Fink, G. T. Gilmore, C. Staley, A. Ward, O. Ali, S. Binderow, S. Cohen, L. A. Grohskopf, L. Paxton, C. E. Hart, and C. S. Dezzutti. 2005. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J. Infect. Dis. 192:1545-1556.
2. Almond, L. M., P. G. Hoggard, D. Edirisinghe, S. H. Khoo, and D. J. Back. 2005. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J. Antimicrob. Chemother. 56:738-744.
3. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. KewalRamani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
4. Andreoletti, L., N. Chomont, G. Gresenguet, M. Matta, J. de Dieu Longo, M. P. Carreno, A. Si-Mohamed, J. Legoff, M. D. Kazatchkine, and L. Belec. 2003. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J. Infect. Dis. 188:549-554.
5. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
6. Balzarini, J., W. G. Brouwer, D. C. Dao, E. M. Osika, and E. De Clercq. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466.
7. Balzarini, J., L. Naesens, E. Verbeken, M. Laga, L. Van Damme, M. A. Parniak, L. Van Mellaert, J. Anne, and E. De Clercq. 1998. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12:1129-1138.
8. Balzarini, J., H. Pelemans, R. Esnouf, and E. De Clercq. 1998. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retrovir. 14:255-260.
9. Barnard, J., G. Borkow, and M. A. Parniak. 1997. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
10. Borkow, G., J. Barnard, T. M. Nguyen, A. Belmonte, M. A. Wainberg, and M. A. Parniak. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71:3023-3030.
11. Borkow, G., D. Arion, M. A. Wainberg, and M. A. Parniak. 1999. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43:259-263.
12. Borkow, G., and M. A. Parniak. October 2001, posting date. Anti-HIV-1 microbicide potential of the tight-binding nonnucleoside reverse transcriptase inhibitor UC781. AIDScience [Online.] http://aidscience.org.
13. Borkow, G., H. Salomon, M. A. Wainberg, and M. A. Parniak. 2002. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res. Hum. Retrovir. 18:711-714.
14. Buckheit, R. W., M. Hollingshead, S. Stinson, V. Fliakas-Boltz, L. A. Pallansch, J. Roberson, W. Decker, C. Elder, S. Borgel, C. Bonomi, R. Shores, T. Siford, L. Malspeis, and J. P. Bader. 1997. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res. Hum. Retrovir. 13:789-796.
15. Buckheit, R. W., Jr., M. J. Snow, V. Fliakas-Boltz, T. L. Kinjerski, J. D. Russell, L. A. Pallansch, W. G. Brouwer, and S. S. Yang. 1997. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:831-837.
16. Buckheit, R. W., Jr., K. Watson, V. Fliakas-Boltz, J. Russell, T. L. Loftus, M. C. Osterling, J. A. Turpin, L. A. Pallansch, E. L. White, J.-W. Lee, S.-H. Lee, J.-W. Oh, H.-S. Kwon, S.-G. Chung, and E-H. Cho. 2001. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 45:393-400.
17. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
18. Cohn, S. E., and R. A. Clark. 2003. Sexually transmitted diseases, HIV, and AIDS in women. Med. Clin. N. Am. 87:971-995.
19. Cunningham, C. K., M. L. Chaix, C. Rekacewicz, P. Britto, C. Rouzioux, R. D. Gelber, A. Dorenbaum, J. F. Delfraissy, B. Bazin, L. Mofenson, and J. L. Sullivan. 2002. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J. Infect. Dis. 186:181-188.
20. D'Cruz, O. J., and F. M. Uckun. 2004. Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 10:315-336.
21. D'Cruz, O. J., T. K. Venkatachalam, and F. M. Uckun. 2000. Novel thiourea compounds as dual-function microbicides. Biol. Reprod. 63:196-205.
22. Dezzutti, C. S., V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
23. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. Glenn Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957.
24. Eshleman, S. H., L. A. Guay, J. Wang, A. Mwatha, E. R. Brown, P. Musoke, F. Mmiro, and J. B. Jackson. 2005. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J. Acquir. Immune Defic. Syndr. 40:24-29.
25. Fletcher, R. S., K. Syed, S. Mithani, G. I. Dmitrienko, and M. A. Parniak. 1995. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4346-4353.
26. Fletcher, R. S., D. Arion, G. Borkow, M. A. Wainberg, G. I. Dmitrienko, and M. A. Parniak. 1995. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry 34:10106-10112.
27. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K.103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29.
28. Girard, M., J. Mahoney, Q. Wei, E. van der Ryst, E. Muchmore, F. Barre-Sinoussi, and P. N. Fultz. 1998. Genital infection of female chimpanzees with human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 14:1357-1367.
29. Henin, Y., L. Mandelbrot, R. Henrion, R. Pradinaud, J. P. Coulaud, and L. Montagnier. 1993. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J. Acquir. Immune Defic. Syndr. 6:72-75.
30. Hossain, M. M., and M. A. Parniak. 2005. In vitro microbicide activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant HIV-1. Abstract from XIV HIV Drug Resistance Workshop, Quebec City, QC, Canada, 2005. Antivir. Ther. 10:S170.
31. Jones, D., N. Parkin, S. E. Hudelson, L. A. Guay, P. Musoke, F. Mmiro, J. B. Jackson, and S. H. Eshleman. 2005. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine. AIDS Res. Hum. Retrovir. 21:319-324.
32. Keller, M. J., M. E. Klotman, and B. C. Herold. 2003. Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am. J. Reprod. Immunol. 49:279-284.
33. Kohno, T., S. Mohan, T. Goto, C. Morita, T. Nakano, W. Hong, J. C. Sangco, S. Morimatsu, and K. Sano. 2002. A new improved method for the concentration of HIV-1 infective particles. J. Viral. Methods 106:167-173.
34. Langmann, P., B. Weissbrich, S. Desch, T. Vath, D. Schirmer, M. Zilly, and H. Klinker. 2002. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur. J. Med. Res. 7:309-314.
35. Lard-Whiteford, S. L., D. Matecka, J. J. O'Rear, I. S. Yuen, C. Litterst, P. Reichelderfer, et al. 2004. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J. Acquir. Immune Defic. Syndr. 36:541-552.
36. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289.
37. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
38. Morris, L., C. Pillay, C. Chezzi, P. Lupondwana, M. Ntsala, L. Levin, F. Venter, N. Martinson, G. Gray, and J. McIntyre. 2003. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS 17:1698-1700.
39. Motakis, D., and M. A. Parniak. 2002. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:1851-1856.
40. Njai, H. F., P. J. Lewi, C. G. Janssen, S. Garcia, K. Fransen, L. Kestens, G. Vanham, and P. A. Janssen. 2005. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antivir. Ther. 10:255-262.
41. Pani, A, C. Musiu, A. G. Loi, A. Mai, R. Loddo, P. La Colla, and M. E. Marongiu. 2001. DABOs as candidates to prevent mucosal HIV transmission. Antivir. Chem. Chemother. 12(Suppl. 1):51-59.
42. Parniak, M. A., and J. Balzarini. 1997. The thiocarboxanilide UC781, a virucidal agent? Int. Antivir. News 5:205-206.
43. Parniak, M. A. 2001. Nonnucleoside reverse transcriptase inhibitors as anti-HIV-1 microbicides. AIDS 15:S56.
44. Pauwels, R., and E. De Clercq. 1996. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:211-221.
45. Pelemans, H., R. Esnouf, A. Dunkler, M. A. Parniak, A.-M. Vandamme, A. Karlsson, E. De Clercq, J. P. Kleim, and J. Balzarini. 1997. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 71:8195-8203.
46. Pollard, R. B., P. Robinson, and K. Dransfield. 1998. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 20:1071-1092.
47. Pope, M., and A. T. Haase. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med. 9:847-852.
48. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-ALDS. Science 224:497-500.
49. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:493-497.
50. Rios, A. March 2004. Method for the development of an HIV vaccine. U.S. patent 20040057930A1.
51. Royce, R. A., A. Sena, W. Cates, Jr., and M. S. Cohen. 1997. Sexual transmission of HIV. N. Engl. J. Med. 336:1072-1078.
52. Sadiq, S. T., S. Fredericks, S. H. Khoo, P. Rice, and D. W. Holt. 2005. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS 19:1716-1717.
53. Tachedjian, G., M. Orlova, S. G. Sarafianos, E. Arnold, and S. P. Goff. 2001. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 98:7188-7193.
54. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11:1077-1097.
55. Van Damme, L. 2004. Clinical microbicide research: an overview. Trop. Med. Int. Health 9:1290-1296.
56. Van Herrewege, Y., J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.
57. Van Herrewege, Y., G. Vanham, J. Michiels, K. Fransen, L. Kestens, K. Andries, P. Janssen, and P. Lewi. 2004. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 48:3684-3689.
58. Van Laethem, K., M. Witvrouw, C. Pannecouque, B. Van Remoortel, J. C. Schmit, R. Esnouf, J. P. Kleim, J. Balzarini, J. Desmyter, E. De Clercq, and A. M. Vandamme. 2001. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS 15:553-561.